Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MeiraGTx

- PMLiVE

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

- PMLiVE

J&J brings its Care4today mobile adherence programme to the UK

Launches the mobile app in its first market outside the US

- PMLiVE

J&J’s Care4Today brand joins Twitter

Firm's Janssen Healthcare Innovation unit also makes its debut on the social network

- PMLiVE

J&J sells diagnostics unit to private equity firm

Ortho-Clinical Diagnostics acquired by the Carlyle Group

- PMLiVE

J&J’s combo diabetes drug held up by FDA

Regulator wants more dosing data on canaglifozin / metformin product

- PMLiVE

FDA clears J&J’s breakthrough lymphoma therapy

Imbruvica approved to treat mantle cell lymphoma

- PMLiVE

J&J pays $2bn to settle Risperdal mis-selling claims

Concludes nine-year investigation into marketing activities

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

J&J seeks European digital health entrepreneurs

Digital health mentor programme will culminate in €50,000 challenge

- PMLiVE

First mAb biosimilars set for European approval

Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

New data backs J&J’s ibrutinib efficacy in B cell cancers

Phase II results showcased at European Hematology Association meeting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links